



#### General Topics

- O Coronary artery disease
- Aortic valve disease
- Mitral valve disease
- Aortic disease
- Heart failure








	CAD-(	Ine	e Ve	esse	el L	1se	ase			
TAB	E1.1 One-Vessel Disease									
104 4000	priate Use Score (1-9)									
••	essel Disease									
		Asymp	Asymptomatic				Ischemic Symptoms			
Indication		Not on AA Therapy or With AA Therapy		Not on AA Therapy		On 1 AA Drug (BB Preferred)		On ≥2 AA Drugs		
		PCI	CABG	PCI	CABG	PCI	CABG	PCI	CABG	
No Pr	oximal LAD or Proximal Left Dominant LCX Involve	ment							-	
1.	■ Low-risk findings on noninvasive testing	R (2)	R (1)	R (3)	R (2)	M (4)	R (3)	A (7)	M (5)	
2	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> </ul>	M (4)	R (3)	M (5)	M (4)	M (6)	M (4)	A (8)	M (6)	
3.	<ul> <li>No stress test performed or, if performed, results are indeterminate</li> <li>FFR ≤0.80*</li> </ul>	M (4)	R (2)	M (5)	R (3)	M (6)	M (4)	A (8)	M (6)	
Proxir	nal LAD or Proximal Left Dominant LCX Involvemen	t Present								
4.	■ Low-risk findings on noninvasive testing	M (4)	R (3)	M (4)	M (4)	M (5)	M (5)	A (7)	A (7)	
5.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> </ul>	M (5)	M (5)	M (6)	M (6)	A (7)	A (7)	A (8)	A (8)	
6.	■ No stress test performed or, if performed, results are indeterminate ■ FFR ≤0.80	M (5)	M (5)	M (6)	M (6)	M (6)	M (6)	A (8)	A (7)	

Market Street	LE 1.2 Two-Vessel Disease										
	priate Use Score (1-9)										
		Asympt	tomatic		Ischemic Symptoms						
		Not on AA Therapy or With AA Therapy		Not on AA Therapy		On 1 AA Drug (BB Preferred)		On ≥2 AA Drugs			
Indication		PCI	CABG	PCI	CABG	PCI	CABG	PCI	CABO		
No Pro	oximal LAD Involvement										
7.	<ul> <li>Low-risk findings on noninvasive testing</li> </ul>	R (3)	R (2)	M (4)	R (3)	M (5)	M (4)	A (7)	M (6		
3.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> </ul>	M (5)	M (4)	M (6)	M (5)	A (7)	M (6)	A (8)	A (7)		
Э.	<ul> <li>No stress test performed or, if performed, results are indeterminate</li> <li>FFR ≤0.80* in both vessels</li> </ul>	M (5)	M (4)	M (6)	M (4)	A (7)	M (5)	A (8)	A (7)		
Proxin	mal LAD Involvement and No Diabetes Present										
10.	<ul> <li>Low-risk findings on noninvasive testing</li> </ul>	M (4)	M (4)	M (5)	M (5)	M (6)	M (6)	A (7)	A (7)		
n.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> </ul>	M (6)	M (6)	A (7)	A (7)	A (7)	A (7)	A (8)	A (8		
12.	<ul> <li>No stress test performed or, if performed, results are indeterminate</li> <li>FFR ≤0.80 in both vessels</li> </ul>	M (6)	M (6)	M (6)	M (6)	A (7)	A (7)	A (8)	A (8		
Proxin	nal LAD Involvement With Diabetes Present										
13.	<ul> <li>Low-risk findings on noninvasive testing</li> </ul>	M (4)	M (5)	M (4)	M (6)	M (6)	A (7)	A (7)	A (8)		
4.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> </ul>	M (5)	A (7)	M (6)	A (7)	A (7)	A (8)	A (8)	A (9		
5.	<ul> <li>No stress test performed or, if performed, results are indeterminate</li> <li>FFR ≤0.80 in both vessels*</li> </ul>	M (5)	M (6)	M (6)	A (7)	A (7)	A (8)	A (7)	A (8		

	CAD-T	me	C V	C221	CI L	7150	case			
TARI	Three-Vessel Disease									
TABLE 1.3 Three-Vessel Disease Appropriate Use Score (1-9)										
	Vessel Disease									
		Asymp	Ischemic Symptoms							
		Not on AA Therapy or With AA Therapy		Not on AA Therapy		On 1 AA Drug (BB Preferred)		On ≥2 AA Drugs		
Indicat	tion	PCI	CABG	PCI	CABG	PCI	CABG	PCI	CABG	
Low Di	isease Complexity (e.g., Focal Stenoses, SYNTAX =	22)								
16.	<ul> <li>Low-risk findings on noninvasive testing</li> <li>No diabetes</li> </ul>	M (4)	M (5)	M (5)	M (5)	M (6)	M (6)	A (7)	A (7)	
17.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> <li>No diabetes</li> </ul>	M (6)	A (7)	A (7)	A (7)	A (7)	A (8)	A (8)	A (8)	
18.	<ul> <li>Low-risk findings on noninvasive testing</li> <li>Diabetes present</li> </ul>	M (4)	M (6)	M (5)	M (6)	M (6)	A (7)	A (7)	A (8)	
19.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> <li>Diabetes present</li> </ul>	M (6)	A (7)	M (6)	A (8)	A (7)	A (8)	A (7)	A (9)	
Interm	ediate or High Disease Complexity (e.g. Multiple F	eatures of Com	plexity as N	oted Previou	sly, SYNTAX	>22)				
20.	<ul> <li>Low-risk findings on noninvasive testing</li> <li>No diabetes</li> </ul>	M (4)	M (6)	M (4)	A (7)	M (5)	A (7)	M (6)	A (8)	
21.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> <li>No diabetes</li> </ul>	M (5)	A (7)	M (6)	A (7)	M (6)	A (8)	M (6)	A (9)	
22.	<ul> <li>Low-risk findings on noninvasive testing</li> <li>Diabetes present</li> </ul>	M (4)	A (7)	M (4)	A (7)	M (5)	A (8)	M (6)	A (9)	
23.	<ul> <li>Intermediate- or high-risk findings on noninvasive testing</li> <li>Diabetes present</li> </ul>	M (4)	A (8)	M (5)	A (8)	M (5)	A (8)	M (6)	A (9)	




#### Blue plate special...




- 3-vessel CABG with insitu LIMA to LAD and SVG to RCA and OM
- Superior to medical management and PCI
  - Multi-vessel
  - Diabetics
  - ) Low EF
  - Anti-platelet intolerance

#### Total Arterial CABG




- O Use of arterial conduits for all bypass grafts
  - Radial artery
  - O RIMA/LIMA
  - Gastroepiploic
- Superior long-term (7-10 yr) survival in selected populations

#### Off-Pump CABG (OP-CAB)




- O CABG without use of the heart-lung machine (CPB)
- Potential benefit in certain patient populations:
  - Renal failure
  - Advanced lung disease
  - O Calcified aorta
- No studies have definitively demonstrated clear benefit over on-pump CABG in general population


#### Minimally Invasive CABG






- Mini-left thoracotomy vs. total endoscopic LIMA to LAD
  - +/- robotic LIMA harvest
  - +/- robotic LIMA to LAD anastomosis
- Potential benefit in certain patient populations where sternotomy is not tolerable
- Often performed as part of hybrid approach with PCI of other vessels







## Treatment Options?


Medical therapy depending on pathology


Diuretics
Afterload reduction
Percutaneous valve therapy
(aortic stenosis ONLY)
Balloon valvuloplasty

Transcatheter AVR (TAVR)

Surgical Valve Therapy

Aortic valve replacement









- Percutaneous approach via 14F sheath
- O Indicated and approved for aortic stenosis and prosthetic valve failure across low - high risk categories
- Several expansion mechanisms
  - O Balloon expandable
  - O Self-expanding (nitinol)
  - Mechanically expandable


#### Surgical AVR





- Sternotomy approach
- Cardiopulmonary bypass and cardiac arrest
- Resection of native valve via aortotomy
- Placement of prosthetic valve
  - Mechanical vs Bioprosthetic
  - Mechanical favored in younger patients <50 yrs
  - Bioprosthetic favored in older patients >60 yrs or those intolerant of anticoagulation

#### TAVR vs. Surgery



- Heart-team based decision with multidisciplinary input
  - Cardiology
  - Cardiac surgery
  - Palliative care
- Significant improvement in outcomes with modern generation devices
  - Mortality
  - Stroke
  - Pacemaker
- Outcome comparable to SAVR for low risk patients...however TAVR is favored for

  - Prior cardiac surgery
  - Multiple co-morbidities
  - Not requiring concomitant coronary revascularization


  - Not likely to need another valve replacement in their lifetime


# Minimally Invasive Surgical AVR








- Right mini-thoracotomy access (Miami Method)
- Femoral cardiopulmonary bypass with cardiac arrest
- Standard valve replacement technique
- Limited to those with primary valve disease without co-existing coronary or other valve lesions
















- Degenerative disease (i.e prolapse, chordal rupture, annular dilitation) typically treated with valve REPAIR
- Stenotic disease (i.e. rheumatic) typically treated with REPLACEMENT
- Infection (endocarditis) typically treated with REPAIR if feasible but most commonly REPLACEMENT
- Placement of prosthetic valve
  - Mechanical vs Bioprosthetic
  - Mechanical favored in younger patients <60 yrs
  - Bioprosthetic favored in older patients >60 yrs or those intolerant of anticoagulation




### Tricuspid Valve Repair Freedom From Moderate or Greater TR (%) 00 00 00 00 00 --- MVR only ---- MVR+TVR





- Current American and European guidelines support tricuspid valve repair if there is annular dilatation(> 40 mm) regardless of severity of regurgitation
  - Chikwe et. al. JACC 2015;65:1931-38
- Typical treatment is concomitant tricuspid ring annuloplasty at time of mitral repair or replacement

#### Maze for Atrial Fibrillation





- Left atrial or bi-atrial Cox-Maze IV lesion sets may be performed at the time of mitral valve surgery for patients with atrial fibrillation to restore sinus rhythm
  - cryo- or radiofrequency ablation energy source
  - left atrial appendage ligation
- Consideration may also be given to patients at high risk for developing AF
  - large left atrium
  - long standing MV disease

